Cadaverine Tartrate

Cadaverine Tartrate

SCHEMBL101303

O.O.O.O.O=C(O)C(O)C(O)C(=O)O

nearest known ligand 0.91

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.91
OR51E2 Q9H255 1/20 0.47
TP53 P04637 1/20 0.47
CYP2C9 P11712 2/20 0.43
PDE4A P27815 1/20 0.43
LMNA P02545 2/20 0.40
CYP2C19 P33261 2/20 0.40
ALDH1A1 P00352 2/20 0.40
NFKB1 P19838 1/20 0.40
THRB P10828 1/20 0.40
RECQL P46063 1/20 0.40
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
ABCB11 O95342 1/20 0.38
F2 P00734 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cadaverine Tartrate SCHEMBL31533366 1.00 TSHR (0.91) TSHROR51E2TP53CYP2C9PDE4A
Cadaverine Tartrate SCHEMBL31314243 1.00 TSHR (0.91) TSHROR51E2TP53CYP2C9PDE4A
Cadaverine Tartrate SCHEMBL30991839 1.00 TSHR (0.91) TSHROR51E2TP53CYP2C9PDE4A
Cadaverine Tartrate SCHEMBL2771868 1.00 TSHR (0.91) TSHROR51E2TP53CYP2C9PDE4A
Cadaverine Tartrate SCHEMBL9133500 1.00 TSHR (0.91) TSHROR51E2TP53CYP2C9PDE4A
Cadaverine Tartrate SCHEMBL31316366 1.00 TSHR (0.91) TSHROR51E2TP53CYP2C9PDE4A
Tartaric Acid SCHEMBL31289378 1.00 TSHR (0.91) TSHROR51E2TP53CYP2C9PDE4A
Cadaverine Tartrate SCHEMBL7776179 1.00 TSHR (0.91) TSHROR51E2TP53CYP2C9PDE4A
Cadaverine Tartrate SCHEMBL905466 1.00 TSHR (0.91) TSHROR51E2TP53CYP2C9PDE4A
Tartaric Acid SCHEMBL29494971 1.00 TSHR (0.91) TSHROR51E2TP53CYP2C9PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118320576-A Carbon dioxide trapping system and heat pump type waste heat regeneration and utilization module thereof 北京大学 2024-07-12 CN claimed
CN-118328587-A Self-heating recycle's carbon dioxide entrapment system 北京大学 2024-07-12 CN claimed
US-20200291040-A1 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF ABBVIE INC (US) 2020-09-17 US claimed
US-20190023714-A1 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-alpha]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF AbbVie Deutschland GmbH & Co. KG (DE) 2019-01-24 US claimed
CN-105025898-B Histamine H4The yl pyrimidines conditioning agent of benzimidazole 2 of acceptor 詹森药业有限公司 2018-01-23 CN claimed
CN-105025898-A Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV 2015-11-04 CN claimed
US-6706122-B2 DISSOLVING INTERMEDIATE CARRIER WITH HYDROGEN PEROXIDE SOLUTION THROUGH PORES UNAXIS TRADING AG (CH) 2004-03-16 US claimed
US-20010013356-A1 Method for removing layers of hard material OERLIKON TRADING AG, TRUBBACH (CH) 2001-08-16 US claimed
WO-1994012624-A1 CRYSTAL CARRIERS FOR CELL CULTURE YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 1994-06-09 WO claimed
US-4425998-A Protective packaging for thermolabile goods using compounds with melting points slightly below thermosensitive temperature of the goods PYMAH CORPORATION (US) 1984-01-17 US claimed
US-20260137097-A1 CHOCOLATE PRODUCTS, INGREDIENTS, PROCESSES AND USES SOC DES PRODUITS NESTLE S A (CH) 2026-05-21 US disclosed
US-12568988-B2 Chocolate products, ingredients, processes and uses SOCIETE DES PRODUITS NESTLE S.A. (CH) 2026-03-10 US disclosed
US-12527333-B2 Foodstuff products, ingredients, processes and uses SOCIETE DES PRODUITS NESTLE S.A. (CH) 2026-01-20 US disclosed
WO-2025262103-A1 SUPERIOR PROMOTERS FOR FUNGAL PROTEIN PRODUCTION BASF SE (DE) 2025-12-26 WO disclosed
EP-4655405-A1 NEW GENOMIC INTEGRATION SITE FOR FUNGAL PROTEIN AND FINE CHEMICALS PRODUCTION BASF SE (DE) 2025-12-03 EP disclosed
EP-0297815-B1 Fluorine containing renin inhibitors PFIZER (US) 1994-07-27 EP disclosed
WO-1994012624-A1 CRYSTAL CARRIERS FOR CELL CULTURE YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 1994-06-09 WO disclosed
US-5203911-A CONTROLLED ELECTROLESS PLATING SHIPLEY COMPANY INC. (US) 1993-04-20 US disclosed
US-4855303-A Fluorine containing renin inhibitors PFIZER INC. (US) 1989-08-08 US disclosed
EP-0297815-A2 Fluorine containing renin inhibitors PFIZER INC. (US) 1989-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200291040-A1 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF CNKSR1, JAK2, TNF TSHR 209/4885OR51E2 4764/4885TP53 1757/4885
US-20190023714-A1 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-alpha]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF CNKSR1, JAK2, TNF TSHR 259/4885OR51E2 4748/4885TP53 2038/4885
US-20260137097-A1 CHOCOLATE PRODUCTS, INGREDIENTS, PROCESSES AND USES TEC, P2RY10, TAS2R10 TSHR 4153/4885OR51E2 2920/4885TP53 3729/4885
US-12568988-B2 Chocolate products, ingredients, processes and uses CROCC, CSPP1, CNOT9 TSHR 4388/4885OR51E2 3899/4885TP53 4074/4885
US-12527333-B2 Foodstuff products, ingredients, processes and uses TREH, LCT, ALPP TSHR 4231/4885OR51E2 4702/4885TP53 3610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.